Immune checkpoint inhibitors(ICIs)have been widely applied in the clinical treatment of various malignant tumors by blocking the tumor immune escape.However,it is followed by increasing immune-related adverse events caused by ICIs.As common ICIs-related cardiovascular adverse reactions,pericardial diseases lead to a relatively high mortality at the acute phase.This article introduces the research progress in recent years on the epidemiology,pathogenesis,clinical characteristics,and treatment principles of ICIs-related pericardial diseases,in order to deepen the clinicians'understandings of this disease.
维普
万方数据